دورية أكاديمية
Tn P Peptide Suppresses Experimental Autoimmune Encephalomyelitis (EAE) in a Preclinical Mouse Model.
| العنوان: | Tn P Peptide Suppresses Experimental Autoimmune Encephalomyelitis (EAE) in a Preclinical Mouse Model. |
|---|---|
| المؤلفون: | Lima C; Immunoregulation Unit of the Laboratory of Applied Toxinology (CeTICs/FAPESP), Butantan Institute, São Paulo, Brazil., Maleski ALA; Immunoregulation Unit of the Laboratory of Applied Toxinology (CeTICs/FAPESP), Butantan Institute, São Paulo, Brazil., Bernardo JTG; Immunoregulation Unit of the Laboratory of Applied Toxinology (CeTICs/FAPESP), Butantan Institute, São Paulo, Brazil., Zelli VC; Immunoregulation Unit of the Laboratory of Applied Toxinology (CeTICs/FAPESP), Butantan Institute, São Paulo, Brazil., Komegae EN; Immunoregulation Unit of the Laboratory of Applied Toxinology (CeTICs/FAPESP), Butantan Institute, São Paulo, Brazil., Lopes-Ferreira M; Immunoregulation Unit of the Laboratory of Applied Toxinology (CeTICs/FAPESP), Butantan Institute, São Paulo, Brazil. |
| المصدر: | Frontiers in immunology [Front Immunol] 2022 Mar 24; Vol. 13, pp. 857692. Date of Electronic Publication: 2022 Mar 24 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Encephalomyelitis, Autoimmune, Experimental* , Multiple Sclerosis*/drug therapy, Animals ; Fingolimod Hydrochloride/therapeutic use ; Glatiramer Acetate/therapeutic use ; Interferon beta-1b/adverse effects ; Mice ; Mice, Inbred C57BL ; Peptides/therapeutic use |
| مستخلص: | Tn P is a family of patented synthetic peptides which is in a preclinical development stage with valuable potential therapeutic indication for multiple sclerosis (MS), an autoimmune demyelinating disease of the central nervous system (CNS). The use of a preclinical animal model, such as experimental autoimmune encephalomyelitis (EAE) has deepened our knowledge of the immunomodulatory functions of Tn P as a drug. We have shown that Tn P possesses a disease suppressive function in EAE, ameliorating disease severity by 40% and suppressing the accumulation of T helper (Th)1- and Th17-producing lymphocytes (by 55% and 60%, respectively) in CNS along with activated microglia/macrophages populations (by 33% and 50%, respectively), and also conferred a protective effect anticipating the remyelination process to day 66 compared to day 83 of untreated cuprizone-mice. Here we expanded our knowledge about its effects compared with current first-line disease-modifying therapies (DMT). We demonstrated that prophylactic treatment with Tn P generated similar protection to betaseron (30%) or was more effective than glatiramer (44% versus 6%) or fingolimod (50% versus 19%) against the development of clinical symptoms. Although Tn P controlled the leukocyte infiltration (87% versus 82%) into demyelinated areas of the spinal cord in the same way as betaseron and fingolimod, it was more effective (72% to 78% decrease) in the long-term control of neuronal degeneration compared to them. Also, when compared to glatiramer, Tn P was more efficient in reversing leukocytes infiltration into the spinal cord (55% versus 24%), as well as induced a higher percentage of regulatory cells in spleen (2.9-fold versus 2.3-fold increase over vehicle-treated EAE mice) an in the spinal cord (8-fold versus 6-fold increase over vehicle-treated EAE mice). This specialized Tn P profile for inducing immune tolerance and neuronal regeneration has significant therapeutic potential for the treatment of MS and other autoimmune diseases. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Lima, Maleski, Bernardo, Zelli, Komegae and Lopes-Ferreira.) |
| References: | Mo Med. 2021 Jul-Aug;118(4):334-339. (PMID: 34373668) Am J Med. 2020 Dec;133(12):1380-1390.e2. (PMID: 32682869) Toxicol Rep. 2020 Dec 10;8:13-22. (PMID: 33364179) Eur J Immunol. 1995 Jul;25(7):1951-9. (PMID: 7621871) J Autoimmun. 2011 Nov;37(3):228-41. (PMID: 21752599) Bioorg Med Chem. 2018 Jun 1;26(10):2700-2707. (PMID: 28720325) Fish Shellfish Immunol. 2021 Jul;114:301-310. (PMID: 33984485) Neurology. 1995 Jul;45(7):1268-76. (PMID: 7617181) Expert Opin Drug Discov. 2019 Nov;14(11):1199-1212. (PMID: 31389262) CNS Drugs. 2016 Feb;30(2):135-47. (PMID: 26715391) J Neurol. 2021 Jul;268(7):2379-2389. (PMID: 32036423) PLoS One. 2017 Jan 26;12(1):e0170825. (PMID: 28125677) Nat Rev Drug Discov. 2021 Apr;20(4):309-325. (PMID: 33536635) Front Immunol. 2019 Jul 11;10:1564. (PMID: 31354720) Drug Discov Today. 2021 Jun;26(6):1409-1419. (PMID: 33647438) Front Mol Biosci. 2021 Oct 21;8:725044. (PMID: 34746229) Pharmaceutics. 2020 Mar 03;12(3):. (PMID: 32138146) Drugs. 2017 Oct;77(16):1755-1768. (PMID: 28905255) Future Med Chem. 2017 Jan;9(2):199-221. (PMID: 28111982) BMC Neurol. 2021 Aug 23;21(1):324. (PMID: 34425763) Neurology. 2007 May 29;68(22 Suppl 3):S32-7; discussion S43-54. (PMID: 17548566) Molecules. 2021 Aug 28;26(17):. (PMID: 34500662) N Engl J Med. 2010 Feb 4;362(5):387-401. (PMID: 20089952) PLoS One. 2017 Feb 24;12(2):e0171796. (PMID: 28235052) Sci Signal. 2012 May 22;5(225):ra38. (PMID: 22623753) Br J Pharmacol. 2009 Nov;158(5):1173-82. (PMID: 19814729) Int J Mol Sci. 2021 Jul 01;22(13):. (PMID: 34281170) |
| فهرسة مساهمة: | Keywords: EAE; TnP; disease-modifying therapies; fish venom; pre-clinical; synthetic peptide |
| المشرفين على المادة: | 0 (Peptides) 145155-23-3 (Interferon beta-1b) 5M691HL4BO (Glatiramer Acetate) G926EC510T (Fingolimod Hydrochloride) |
| تواريخ الأحداث: | Date Created: 20220411 Date Completed: 20220412 Latest Revision: 20220705 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8988151 |
| DOI: | 10.3389/fimmu.2022.857692 |
| PMID: | 35401524 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2022.857692 |